Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Apellis Pharmaceuticals : Announces Pricing of Public Offering of Common Stock - Form 8-K

11/17/2021 | 01:10pm EST

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) - Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 8,750,000 shares of its common stock at a public offering price of $40.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1,312,500 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on November 18, 2021, subject to customary closing conditions.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated, Oppenheimer & Co. Inc. and Raymond James & Associates, Inc. are acting as lead managers for the offering.

The shares are being offered by Apellis pursuant to an automatically effective shelf registration statement that was filed with the Securities and Exchange Commission ("SEC") on January 7, 2020. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC's website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or Evercore Group L.L.C., Attention: ECM General Counsel, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the anticipated closing date of the public offering. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and other factors discussed in the "Risk Factors" section of the preliminary prospectus supplement filed with the SEC on November 15, 2021, Apellis' Quarterly Report on Form 10-Q filed with the SEC on November 8, 2021, and the risks described in other filings that Apellis may make with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:

Lissa Pavluk



Investor Contact:

Meredith Kaya




Apellis Pharmaceuticals Inc. published this content on 17 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2021 17:59:35 UTC.

ę Publicnow 2021
01/11Raymond James Adjust Apellis Pharmaceuticals' Price Target to $112 from $116, Keeps Str..
01/10Pfizer CEO says Omicron-targeted vaccine is most likely outcome
01/10APELLIS PHARMACEUTICALS : Excerpt from corporate presentation dated January 2022 - Form 8-..
01/10Pfizer CEO says Omicron-targeted vaccine is most likely outcome
01/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
01/03Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021INSIDER SELL : Apellis Pharmaceuticals
2021Aspaveli (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
2021Certain Common Stock of Apellis Pharmaceuticals, Inc. are subject to a Lock-Up Agreemen..
2021Certain Stock Options of Apellis Pharmaceuticals, Inc. are subject to a Lock-Up Agreeme..
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 14,6 M - -
Net income 2021 -724 M - -
Net cash 2021 185 M - -
P/E ratio 2021 -4,42x
Yield 2021 -
Capitalization 3 740 M 3 740 M -
EV / Sales 2021 243x
EV / Sales 2022 28,8x
Nbr of Employees 486
Free-Float 82,3%
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | APLS | US03753U1060 | MarketScreener
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 17
Last Close Price 38,41 $
Average target price 70,13 $
Spread / Average Target 82,6%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CSL LIMITED-5.85%94 127
BIOGEN INC.-2.55%34 345